Canadian Trial of Dietary Carbohydrates in Diabetes

September 21, 2005 updated by: University of Toronto

Long-Term Effect of Altering the Source or Amount of Dietary Carbohydrate in Type 2 Diabetes

A long-term low carbohydrate, high monounsaturated fat diet, compared to a high carbohydrate, low glycemic index diet, results in more rapid progression of diabetes; i.e. increased fasting glucose and glycated hemoglobin, reduced beta-cell function and insulin sensitivity and increased free fatty acids. The deleterious effects of a high carbohydrate diet on plasma lipids are only temporary and do not persist beyond 6 months. A long-term high carbohydrate, low glycemic index diet, compared to a high carbohydrate, high glycemic index diet, improves glycemic control and beta-cell function

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment

168

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Alberta
      • Edmonton, Alberta, Canada, T6G 2C8
        • Clinical Trials Centre
    • Ontario
      • London, Ontario, Canada, N6G 2M3
        • St. Joseph's Health Centre
      • Toronto, Ontario, Canada, M5B 1W8
        • St. Michael's Hosptial
    • Quebec
      • Montreal, Quebec, Canada, H2W 1T8
        • Hotel Dieu
      • Sherbrooke, Quebec, Canada, J1H 5N4
        • Centre Universitaire de Sante de l'Estrie

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • male or non-pregnant/non-lactating females with type 2 diabetes treated by diet alone
  • age 53-75y
  • body mass index 25-40kg/m^2 (Caucasian) or 23-40kg/m^2 (other)
  • HbA1c <=130% of upper limit of normal of local hospital lab

Exclusion Criteria:

  • use of any hypoglycemic or anti-hyperglycemic drug within 6 months of randomization
  • major cardiovascular event or major surgery within 6 months of randomization
  • serum triglycerides >10mmol/L
  • presence of other major debilitating disorder such as liver disease, renal failure or cancer
  • presence of gastrointestinal disorder or use of drug which is likely to alter gastrointestinal motility or nutrient absorption
  • use of oral steroids
  • substance or alcohol abuse
  • simultaneous participation in another clinical trial
  • allergy or intolerance to more than one of wheat, barley, corn, oats, potato, legumes, nuts, psyllium, olives, avocado or canola
  • unwilling or unable to follow the protocol and/or give informed consent
  • subjects planning to be on holiday for more than 8 weeks in a row or a total of 12 weeks in the year in locations to which they will not take study food

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

What is the study measuring?

Primary Outcome Measures

Outcome Measure
glycated hemoglobin

Secondary Outcome Measures

Outcome Measure
quality of life
Body weight
fasting glucose
waist circumference
occurrence of diet failure
fasting C-reactive protein
fasting lipids (total, HDL and LDL cholesterol and triglcyerides)
fasting apolipoproteins A1 and B100
fasting free fatty acids
fasting short chain fatty acids
plasma glucose and insulin 30, 60 and 120min after 75g oral glucose
insulin sensitivity (HOMA)
beta-cell function (30min-fasting insulin)/(30min-fasting glucose)
metabolic profile (glucose, insulin, triglycerides and FFA during 8h profile)
gastrointestinal symptoms
diet satisfactio

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Toronto

Investigators

  • Principal Investigator: Thomas MS Wolever, MD, PhD, University of Toronto/St. Michael's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2002

Study Completion

October 1, 2004

Study Registration Dates

First Submitted

September 20, 2005

First Submitted That Met QC Criteria

September 21, 2005

First Posted (Estimate)

September 22, 2005

Study Record Updates

Last Update Posted (Estimate)

September 22, 2005

Last Update Submitted That Met QC Criteria

September 21, 2005

Last Verified

September 1, 2005

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 44205

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 2 Diabetes

Clinical Trials on Control - high carbohydrate, high glycemic index foods

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe